Guo Rui Yinuo has been approved to join the Qin Chuangyuan “Scientists + Engineers” team.
Release time:
2024-03-15 18:36
Keywords:
Medication,Science
On March 12, 2024, the Shaanxi Provincial Department of Science and Technology announced the list of teams selected for the 2024 Qin Chuang Yuan “Scientists + Engineers” program. The “Research Team on Key Common Technologies for Pharmacological Evaluation of Inhaled Drugs—Scientists + Engineers” from Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd. was approved for inclusion.
This selection was conducted in accordance with the requirements of the "Construction Plan for the 'Scientists + Engineers' Team of Qin Chuangyuan" (Shaanxi Science and Technology Development [2021] No. 16) and the "Notice on Soliciting Projects for the 2024 Shaanxi Provincial Science and Technology Development Plan (First Batch)" (Shaanxi Science and Technology Development [2023] No. 6). After unit applications, recommendation reviews, expert evaluations, and approval by the Department's executive meeting, 198 entities—including Shaanxi Zinc Industry Co., Ltd. and Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.—were designated to lead the formation of the Qin Chuangyuan "Scientists + Engineers" team.
In July 2021, Guorui Yinuo obtained the Drug GLP (Good Laboratory Practice for Non-Clinical Studies) certification from the National Medical Products Administration, becoming the first non-clinical safety research institution in the province to pass the national Drug GLP certification. This achievement fills a gap in GLP laboratories in our province and will establish a convenient, efficient, and reliable technical platform for new drug development and preclinical safety evaluation in Shaanxi Province’s pharmaceutical industry. It will play a crucial role in further enhancing Shaanxi Province’s drug R&D capabilities, its independent innovation capacity in the pharmaceutical industry, and the quality of drug research. As an important intermediate link in the transformation of innovative drugs from the innovation chain to the industrial chain, drug safety evaluation research serves as a bridge connecting the interaction and integration of the “Qin Chuangyuan” initiative’s innovation chain and industrial chain in the life sciences sector, holding significant value for the development of the province’s life science industry. The following are the key qualifications and certifications currently held by Guorui Yinuo:
Passed the veterinary drug GLP inspection by the Ministry of Agriculture and Rural Affairs of China in August 2022.
In March 2023, we were honored with the title of “Qin Chuang Yuan Two-Chain Integration ‘Promoter’” by the Qin Chuang Yuan Innovation-Driven Platform in Xi'an City.
In March 2023, it was recognized by the Xi'an Municipal Bureau of Industry and Information Technology as an innovative small and medium-sized enterprise in Shaanxi Province for 2022.
In May 2023, we became a “Director Unit” of the Shaanxi Provincial Society of Toxicology and established the “Specialist Committee for Drug Toxicology and Safety Evaluation.”
In May 2023, obtained the Certificate of Conformity to Good Laboratory Practice (GLP) from the China National Accreditation Service for Conformity Assessment (CNAS).
In September 2023, it was recognized by the Xi'an Science and Technology Bureau as a “Xi'an Engineering and Technology Research Center for 2022.”
In December 2023, it was recognized by the Xi'an Science and Technology Bureau as a “New-Type R&D Institution of Xi'an.”
Passed the National Veterinary Drug GCP Certification by the Ministry of Agriculture and Rural Affairs in December 2023.
Guorei Yinuo integrates drug toxicology, pathology, pharmacology, analytical testing, cosmetics, and bioequivalence evaluation services for generic drugs, possessing tremendous growth potential. In August 2019, it was recommended by the Airport New City Management Committee of Xixian New Area, Shaanxi Province, as a “key enterprise poised for IPO.” The company’s building area reaches 6,000 square meters, and its Phase I investment exceeds 30 million yuan. Currently, it is equipped with over 300 pieces of instrumentation and equipment, including liquid chromatography-mass spectrometry systems, high-performance liquid chromatographs, fully automated chemiluminescence immunoassay analyzers, animal blood analyzers, automatic tissue dehydrators, microbalances capable of measuring to one-millionth of a gram, animal oral and nasal inhalation exposure systems, UV-Vis spectrophotometers, fluorescence microscopes, and more. The company has established experimental platforms covering genetic toxicology, analytical testing, reproductive toxicology, and clinical pathology. We are dedicated to non-clinical safety evaluation of pharmaceuticals, offering clients a one-stop service that includes personalized protocol design, drug screening, pharmacodynamic studies, pharmacokinetic studies, safety assessments, and clinical trial sample analysis. We also provide safety evaluation services for foods, health supplements, cosmetics, and medical devices. Furthermore, our company has set up platforms for developing disease model animals and breeding laboratory animals. We have assembled a stable, experienced, and highly qualified professional team and have established a GLP-compliant system that simultaneously meets the regulatory requirements of the U.S. FDA, OECD, and China’s NMPA.
Related News
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681